Clinical trials: Rosuvastatin
Type IIa and IIb Hypercholesterolaemia
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
The purpose of this study is to evaluate the efficacy and safety of Rosuvastatin 5 mg as an hypercholesterolemia treatment comparatively at 2 other statins: Pravastatin 40 mg and Atorvastatin 10 mg.
- Trial name
- CAP-Chol (NCT00631189)
- Testing
- Rosuvastatin, Pravastatin, Atorvastatin
- Where
- 170 sites in France
- Volunteers
- 668 people
- Sponsor
- AstraZeneca
Chronic Periodontitis
Platelet-rich Fibrin With 1.2% Rosuvastatin in Chronic Periodontitis Treatment
The present study is designed to evaluate the combined efficacy of Platelet Rich Fibrin (PRF) and 1.2% Rosuvastatin (RSV) with open flap debridement (OFD) in treatment of intrabony defects in chronic periodontitis patients
- Trial name
- NCT02645227
- Testing
- Open flap debridement (OFD), OFD with Platelet rich fibrin (PRF), OFD with PRF and 1.2% Rosuvastatin
- Where
- India
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Government Dental College and Research Institute, Bangalore
Coronary Artery Dissection, Spontaneous
Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD
An emerging cause of heart attack in young women is a dissection (or tear) in the coronary arteries. Many of these young women continue to have chest pain long after the tear has healed and this is thought to be due to problems…
- Trial name
- SAFER-SCAD (NCT02008786)
- Testing
- ramipril, rosuvastatin
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Cardiology Research UBC
Intracranial Artery Stenosis
Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome
sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C>1.8mmol/L) without…
- Trial name
- sICASBLM (NCT05397405)
- Testing
- PCSK9 inhibitor
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University